Effect of genetic variation in SNCA and APOE on cerebrospinal fluid protein levels in patients with Parkinson’s disease and controls
Objective: To determine whether genetic variability constitutes a source of heterogeneity in levels of cerebrospinal fluid (CSF) proteins in patients with Parkinson's disease (PD) and…Characteristics of the interaction between different toxic aggregated species of alpha-synuclein and cell membrane
Objective: To determine (1) the interaction rate of each toxic aggregated species of alpha-synuclein (α-Syn) with cell membrane compare to the monomeric form, (2) the…Inhibition of cathepsin D enhances the autophagy lysosome pathway dysfunction and α-synuclein aggregation in experimental parkinsonism
Objective: To explore the mechanism of CTSD inhibition in the dysfunction of autophagy-lysosome pathway and aggregation of α-synuclein in Parkinson's disease. Background: α-synuclein, the main…Assessment of Parkinson’s disease risk loci as DNA methylation quantitative trait loci
Objective: To gain potential mechanistic insight into the pathogenesis of Parkinson's disease (PD), a map of DNA methylation in normal human brain assessing 486,428 CpG…Differential vulnerability to α-synuclein pathology among neuronal subpopulations
Objective: To identify the cell death pathway(s) activated by α-synuclein (α-syn) pathology in an in vitro model of Lewy pathology and determine if neuronal subpopulations…Human-derived α-synuclein antibody BIIB054 binds pathologic forms of α-synuclein and attenuates transmission of α-synuclein in vitro and in vivo
Objective: To identify and characterize a human antibody against α-synuclein (α-syn) for the clinical development of an immunotherapy for Parkinson's disease (PD). Background: α-syn plays…
- « Previous Page
- 1
- …
- 58
- 59
- 60